---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-108806"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:19:53.839311+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ironwood Q3 LINZESS sales up 40% YoY to $315M; raises full-year guidance

## Summary
- Q3 GAAP net income $40M ($0.23 diluted EPS) vs $3.6M a year ago; adjusted EBITDA $82M vs $34.5M.
- LINZESS US net sales $315M (+40% YoY); EUTRx demand growth +12% YoY.
- Raises FY2025 LINZESS net sales guidance to $860-$890M; total revenue $290-$310M; adjusted EBITDA >$135M.
- FDA approved LINZESS for IBS-C in children ages 7+; first drug for that indication.
- Plans to align with FDA on apraglutide Phase 3 trial design, start confirmatory study H1 2026; strategic alternatives review ongoing.

## SEC filing metadata
- accession: 0001104659-25-108806
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465925108806/0001104659-25-108806-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465925108806/tm2530577d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-108806
- JSON: https://secwatch.observer/filing/0001104659-25-108806.json
- Plain text: https://secwatch.observer/filing/0001104659-25-108806.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.